Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
|Articles|May 17, 2023
Pharma USA 2023: Conversational AI
In this interview, Arun Thachi, Director, Head of IT Marketing and Sales, Boehringer Ingelheim, discusses the AI journey in pharma.
Advertisement
Arun Thachi, Director, Head of IT Marketing and Sales, Boehringer Ingelheim, explains conversational AI and how it can be best-used in pharma to inform and engage.
Advertisement
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
FDA Pauses Commissioner’s National Priority Voucher Program: Report
3
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
4
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
5